Last Updated : July 24, 2024
Details
Generic Name:
capmatinib
Project Status:
Not filed
Therapeutic Area:
Metastatic non-small cell lung cancer (NSCLC)
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Tabrecta
Project Line:
Reimbursement Review
Project Number:
NS0036-000
Biosimilar:
No
Submission Type:
Non-submission
Fee Schedule:
N/A
Indications:
Treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : July 24, 2024